114095-04-4

Basic information

• Product Name: IMIDAZO[2,1-B]BENZOTHIAZOLE-2-CARBOXALDEHYDE
• Synonyms: IMIDAZO[2,1-B]BENZOTHIAZOLE-2-CARBOXALDEHYDE;Benzo[d]iMidazo[2,1-b]thiazole-2-carbaldehyde
• CAS NO: 114095-04-4
• Molecular Formula: C₁₀H₆N₂OS
• Molecular Weight: 202.23
• Mol File: 114095-04-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 208-209 °C
• Appearance: /
• Density: 1.49±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.14±0.40(Predicted)
• CAS DataBase Reference: IMIDAZO[2,1-B]BENZOTHIAZOLE-2-CARBOXALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: IMIDAZO[2,1-B]BENZOTHIAZOLE-2-CARBOXALDEHYDE(114095-04-4)
• EPA Substance Registry System: IMIDAZO[2,1-B]BENZOTHIAZOLE-2-CARBOXALDEHYDE(114095-04-4)

Safety Data

• Hazardous Substances Data: 114095-04-4(Hazardous Substances Data)

Usage

General Description

Imidazo[2,1-b]benzothiazole-2-carboxaldehyde is a chemical compound that belongs to the imidazole family and contains a benzothiazole ring. It is commonly used in the synthesis of pharmaceuticals, agrochemicals, and dyes due to its diverse range of biological and chemical properties. The compound has been reported to exhibit antimicrobial, antifungal, and anticancer activities, making it a valuable building block in the development of various therapeutic agents. Imidazo[2,1-b]benzothiazole-2-carboxaldehyde has also been studied for its potential as a fluorescent probe for detecting metal ions and as an inhibitor of certain enzymes. Due to its versatile applications, this chemical has attracted significant attention in the fields of medicinal chemistry and chemical biology.

Upstream product

• 136-95-8 2-amino-benzthiazole 
• 114095-02-2 imidazo[2,1-b]benzothiazole-2-methanol 
• 21224-16-8 2-amino-6-ethylbenzo[d]thiazole 
• 64951-05-9 ethyl imidazo[2,1-b]-benzthiazole-2-carboxylate 

Downstream Products

• 114094-91-6 Benzo[d]imidazo[2,1-b]thiazol-2-yl-phenyl-methanone 
• 623906-22-9 4-nitrobenzyl 6-[(acetyloxy)(imidazo[2,1-b][1,3]benzothiazol-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicylco[3.2.0]hept-2-ene-2-carboxylate 

Relevant articles and documents

Discovery of novel Tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats

Tricyclic analogues were rationally designed as the high affinity niacin receptor G-protein-coupled receptor 109A (GPR109A) agonists by overlapping three lead structures. Various tricyclic anthranilide and cycloalkene carboxylic acid full agonists were di

Structure-activity relationship of 6-methylidene penems bearing tricyclic heterocycles as broad-spectrum β-lactamase inhibitors: Crystallographic structures show unexpected binding of 1,4-thiazepine intermediates

The design and synthesis of a series of seven tricyclic 6-methylidene penems as novel class A and C serine β-lactamase inhibitors is described. These compounds proved to be very potent inhibitors of the TEM-1 and AmpC β-lactamases and less so against the class B metallo-β-lactamase CcrA. In combination with piperacillin, their in vitro activities enhanced susceptibility of all class C resistant strains from various bacteria. Crystallographic structures of a serine-bound reaction intermediate of 17 with the class A SHV-1 and class C GC1 enzymes have been established to resolutions of 2.0 and 1.4 A?, respectively, and refined to R-factors equal 0.163 and 0.145. In both β-lactamases, a seven-membered 1,4-thiazepine ring has formed. The stereogenic C7 atom in the ring has the R configuration in the SHV-1 intermediate and has both R and S configurations in the GC1 intermediate. Hydrophobic stacking interactions between the tricyclic C7 substituent and a tyrosine side chain, rather than electrostatic or hydrogen bonding by the C3 carboxylic acid group, dominate in both complexes. The formation of the 1,4- thiazepine ring structures is proposed based on a 7-endo-trig cyclization.

HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS ΒΕΤΑ-LACTAMASE INHIBITORS

The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.